Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meet
2010-11-20
(Press-News.org) MONTREAL, CANADA - November 19, 2010 - Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting.
Physicians delivered the investigational TTF therapy to patients in the study using the NovoTTF-100A – a portable, non-invasive medical device. Investigators conducted this phase III study under an approved IDE at 28 centers in the US, Europe, and Israel, enrolling 237 patients with glioblastoma tumors that had recurred or progressed after initial treatment. Patients randomly received TTF therapy alone or an effective chemotherapy selected by physicians. The results reported today expand on headline data from the trial presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in June 2010, which suggested that TTF therapy may be as effective as the best available chemotherapy in extending overall survival of patients with recurrent GBM.
"The study suggests that patients treated with TTF therapy, as defined in the protocol, lived significantly longer than patients treated with the currently available best chemotherapeutic regimens," said Professor Ram. "Interestingly, younger patients and patients with better functional status appear to have an impressive survival advantage. In these patients the incidence of radiological tumor response to TTF therapy was double that seen in patients treated with chemotherapy. Most importantly, in addition to the survival benefit, treatment with TTF therapy was associated with significantly better quality of life compared to patients receiving chemotherapy."
Patients under the age of 60 who were able to maintain normal daily activities (KPS>80 percent) at the time of enrollment achieved a significant increase in median overall survival time (8.8 vs. 6.6 months, n=110, p< 0.01) and in the 1-year survival rate (35 percent vs. 20 percent, n=110, p< 0.01) when treated with TTF Therapy versus effective chemotherapies. TTF therapy also produced a significant increase in survival time for patients who had failed treatment with bevacizumab (Avastin; Roche) prior to enrollment (4.4 vs. 3.1 months, n=44, p< 0.02). Patients enrolled in the study also reported superior quality of life scores (EORTC QLQ-C30) across a range of lifestyle and symptom categories for TTF therapy compared to the chemotherapy-treated control group.
"The data presented at SNO further validate TTF therapy as a potential treatment option for patients with recurrent glioblastoma tumors," said Asaf Danziger, chief executive officer of Novocure, the trial sponsor. "The suggested improvement in quality of life scores reported by patients receiving TTF therapy is particularly important given the nature of this disease and the strong desire among patients and their caregivers to avoid the side-effects of chemotherapy and radiation."
TTF therapy has been shown in vitro to slow and reverse tumor cell proliferation by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low-intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.
Novocure is now sponsoring a second phase III study of TTF therapy at 26 centers in the US, Europe, and Israel. This study will enroll 283 patients with newly diagnosed glioblastoma tumors. Patients will be randomized (2 to 1) to receive TTF therapy and temozolomide (Temodar; Merck & Co) or temozolomide alone (the current best standard of care).
Novocure also recently reported results from a successful phase II trial that studied TTF therapy in combination with chemotherapy for advanced non-small cell lung cancer at the European Society of Medical Oncology Congress.
The NovoTTF-100A is an investigational device in the United States and has not been approved by the U.S. Food and Drug Administration (FDA) for sale in the US for any use. Results of this phase III trial for recurrent glioblastoma patients have been submitted in a premarket approval application, which is under review by FDA. Novocure currently has CE Mark for the NovoTTF-100A and the treatment is available to patients in Europe.
INFORMATION:
ABOUT NOVOCURE
Novocure is a subsidiary of Jersey Isle based Standen Ltd., an oncology company pioneering Tumor Treating Fields (TTF) therapy, a new modality for treating solid tumors. Novocure's US operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel. For additional information about the ongoing phase III trial for newly diagnosed glioblastoma patients, please visit www.novocuretrial.com.
For additional information about the company, please visit www.novocure.com.
EDITORS NOTE: High resolution device photos available by request.
ELSE PRESS RELEASES FROM THIS DATE:
2010-11-20
New Rochelle, NY, November 19, 2010—Mounting evidence linking childhood obesity to an increasing risk of obesity, heart disease, type 2 diabetes, and other cardiovascular and metabolic disorders in adulthood is clearly presented in a comprehensive review article in the current issue of Childhood Obesity, published by Mary Ann Liebert, Inc. The article is available free online.
Authors Megan Moriarty-Kelsey, MD and Stephen Daniels, MD, PhD, Department of Pediatrics, University of Colorado School of Medicine, caution that the rising prevalence of obesity in children will ...
2010-11-20
An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.
More than 90 percent of sporadic (non-inherited) colon cancers – the second deadliest type of cancer in the developed world – are caused by mutations that result in inappropriate activation of the Wnt (pronounced "wint") signaling pathway. Blocking ...
2010-11-20
JUPITER, FL, November 19, 2010 – Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.
The study was published in the November issue (Volume 5, Issue 11) of the journal ACS Chemical Biology.
"This new compound is particularly important because it works in vivo, ...
2010-11-20
FORT COLLINS - In the last 50 years, modern medicine has made astounding advances in surgery, yet many of today's veterinary and human medicine students still hone basic surgical and suturing skills on carpet pads and pig's feet before transitioning to a live patient. An invention by Colorado State University veterinarians provides students with artificial body parts that look, feel, behave, and even bleed just like real skin, muscles and vessels.
The artificial replicas of sections of human and animal bodies -- such as an abdominal wall -- give students a realistic learning ...
2010-11-20
HOUSTON, Nov. 19, 2010 – University of Houston (UH) physicists are using complex computer simulations to illuminate the workings of a crucial protein that, when malfunctioning, may cause Alzheimer's and cancer.
Margaret Cheung, assistant professor of physics at UH, and Antonios Samiotakis, a physics Ph.D. student, described their findings in a paper titled "Structure, function, and folding of phosphoglycerate kinase (PGK) are strongly perturbed by macromolecular crowding," published in a recent issue of the journal Proceedings of the National Academy of Sciences, one ...
2010-11-20
Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also represents another step towards new organ replacement therapies.
The research, led by Dr Arun Sharma and Earl Cheng from the Feinberg School of Medicine at Northwestern University and Children's Memorial Research Center, focused on bone marrow mesenchymal stem cells (MSCs) taken from ...
2010-11-20
CORVALLIS, Ore. – The first study to ever explore biological activity in the deepest layer of ocean crust has found bacteria with a remarkable range of capabilities, including eating hydrocarbons and natural gas, and "fixing" or storing carbon.
The research, just published in the journal PLoS One, showed that a significant number and amount of bacterial forms were present, even in temperatures near the boiling point of water.
"This is a new ecosystem that almost no one has ever explored," said Martin Fisk, a professor in the College of Oceanic and Atmospheric Sciences ...
2010-11-20
COLLEGE STATION - Functional amino acids play a critical role in the development of both animals and humans, according to a Texas AgriLife Research scientist.
In a journal article appearing in the American Society for Nutrition (Advances in Nutrition 1:31-37, 2010), Dr. Guoyao Wu, AgriLife Research animal nutritionist and senior faculty fellow in the department of animal science at Texas A&M University, calls for scientists to "think out of the box" and place more emphasis on this area of study.
"We need to move forward and capitalize on the potential of functional ...
2010-11-20
Though it's been at least a billion years since plants and animals shared a common ancestor, they have through the eons shared a common threat in the form of microbes, including bacteria, eukaryotes and viruses. This has resulted in remarkably similar mechanisms for detecting the molecular signatures of infectious organisms that hold promise for the future treatment of infectious diseases in humans.
The recognition of microbial signature molecules by host receptors is the subject of a paper published in the journal Science titled "Plant and Animal Sensors of Conserved ...
2010-11-20
1. Kidney Disease Patients Benefit from a Diet High in Fruits and Vegetables
Healthy Foods Can Help Maintain Kidney Function
In patients with kidney disease, the Western diet produces an acidic environment in the body that has numerous negative effects and worsens with age as kidney function declines. Nimirit Goraya, MD (Texas A&M College of Medicine and Scott and White Healthcare) and her colleagues conducted a study to see if consuming a diet high in fruits and vegetables that counteract this acidity might improve the kidney health of 40 patients who have moderately ...
LAST 30 PRESS RELEASES:
[Press-News.org] Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meet
